Loading patent…
AssigneeSorrento Therapeutics, Inc.
InventorsRandy Gastwirt, Heyue Zhou, Guodi Lu
Estimating the term…
There is disclosed compositions and methods relating to or derived from anti-IGF1R antibodies. More specifically, there is disclosed fully human antibodies that bind IGF1R, IGF1R-binding fragments and derivatives of such antibodies, and IGF1R-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF1R related disorders or conditions, including various inflammatory disorders and various cancers.
A recombinant fully human antibody of an IgG class that binds to an insulin-like growth factor receptor 1(IGF1R) epitope, that has
A fully human Fab antibody fragment having a variable domain region from a heavy chain and a variable domain region from a light chain, wherein the Fab antibody fragment has
A single chain human antibody having a variable domain region from a heavy chain and a variable domain region from a light chain and a peptide linker connecting the heavy chain and light chain variable domain regions, wherein the single chain human antibody has
Dependencies are inferred from the claim text.